NATCO Pharma Limited (NATCOPHARM): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for NATCO Pharma Limited, explained in plain English.
- NATCO Pharma Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- NATCOPHARM closed at ₹814.30 on 20 November 2026.
- Over the past year the shares are down 6.3%, trading between ₹773.60 and ₹1,226.80.
- Reported fundamentals show return on equity of 9.01%, a net margin of 26.79%, debt to equity of 10.58.
- Our Pulse grade checklist scores it D (41/100) across momentum, growth, profitability and safety on fixed thresholds.
- Annualised volatility over the past year is 35.32% with a maximum drawdown of -35.19% and a beta of 0.8 against NIFTY 50.
- Recent coverage: Stock Market Today: Sensex Off Highs, Up 300 Points, Nifty 50 Near 25,200; Natco Pharma Zooms 7%, Kaynes Tanks 10%
- Recent coverage: Natco Pharma Q2 Results: Net Profit Falls 61% To Rs 203 Crore, Revenue Declines 29%; Stock Tumbles 3%
Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma
Last traded values from 20 Nov 2026. Closed — weekend.
Pharma & Healthcare · Drug Manufacturers - Specialty & Generic
NATCO Pharma Limited (NATCOPHARM)
₹814.3
▼ 7.65 (-0.93%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Neutral momentum · 3/51M
+1.68%
3M
-7.20%
6M
-29.58%
1Y
-6.33%
Where it sits in its 52-week range
8%Below 52-week high
32.5%
4.2% above the low
Momentum read
Neutral
3/5 checks passed
52-wk high
₹1,206
52-wk low
₹781.6
Market cap
₹15,974 Cr
P/E (trailing)
17.7
Dividend yield
—
ROE
9.01%
Profit margin
26.79%
Revenue growth
-29%
Price / Book
1.49
Debt / Equity
10.58
EPS (TTM)
45.89
Book value
₹545.11
Beta
0.81
Pulse grade: D, 41 out of 100
Momentum
C- ✓Trading above 50-day average
- ✕Trading above 200-day average
- ✓RSI in healthy 45-70 zone
- ✕Positive 3-month return
Growth
F- ✕Revenue growth above 12%
- ✕Revenue growing above 5%
- ✕Quarterly profits trending up
Profitability
D- ✕Return on equity above 18%
- ✕Return on equity above 12%
- ✓Profit margin above 12%
Safety
A- ✓Debt below 50
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹967 crore · net profit ₹203 crore · margin 21.0%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
NATCOPHARM headlines
No NATCOPHARM stories right now.
NATCOPHARM filings & announcements
NATCOPHARM, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
35.32%
Sharpe ratio
-0.09
Sortino ratio
-0.13
Max drawdown
-35.19%
Daily VaR (95%)
-2.93%
CAGR (1Y)
-3.22%
Return skew
-0.36
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.